Posting Block

LOS ANGELES--(BUSINESS WIRE)--Auriga Laboratories, Inc. (OTCBB:ARGA), a specialty pharmaceutical company with products for the treatment of acute respiratory diseases, dermatological conditions, and xerostomia, announced today the launch of Xyralid(TM) RC (lidocaine HCL 3%/hydrocortisone acetate 1%) rectal cream kit, a convenience kit that contains a seven- day supply (14 units) of Xyralid Rectal Cream and a 7 day supply of Konsyl® Natural Bulk-Forming Laxative with a convenient shaker cup. Xyralid RC will be promoted to Gastroenterologists and Colon Rectal Specialists by the recently announced 46-person ATS Pharmaceutical division of Auriga. According to Wolters Kluwer Health, Inc., the overall US hemorrhoid prescription market exceeds $88 million annually. The American Society of Colon & Rectal Surgeons (ASCRS) recommends increasing the amount of fiber and fluids in the diet to relieve mild hemorrhoid symptoms1.

Konsyl® Natural Bulk-Forming Laxative, unlike other products that contain fillers or artificial sweeteners, contains 100% psyllium. Konsyl® utilizes the psyllium husk - the most hydrophilic part of the psyllium plant. Each teaspoon dose contains 6.0 grams of psyllium, providing more fiber per dose than any other bowel normalizer. Konsyl contains no sugar, sugar substitutes, or any other additives. It is very low in sodium, requires fewer daily doses, only contains 3 calories per dose, is safe for pregnant women, is recommended for diabetic patients, is an excellent stool softener and helps lower cholesterol levels.

"We believe that Xyralid RC represents an attractive product in a growing market that is ideally positioned for the sales force we have attracted to our ATS division," said Philip S. Pesin, CEO of Auriga. "Xyralid RC Kit offers the convenience of packaging Konsyl® Natural Bulk-Forming Laxative with Xyralid Rectal Cream to create a unique hemorrhoid convenience kit."

Konsyl Pharmaceuticals, Inc. manufactures Konsyl® concentrated psyllium fiber, a fiber laxative that has been doctor recommended for over 45 years. Konsyl® is one of the leading brands in the Fiber Category in Retail Food, Drug & Mass Stores. Psyllium fiber is recognized as the 'best choice' for people with medical conditions affecting their GI health.

Auriga's recently formed ATS Pharmaceuticals (Advanced Topical Solutions) division is a 46-person sales force with a dedication to Dermatologists, Gastroenterologists and Colon-Rectal Specialists. Xyralid RC is the second product being sold by ATS and the Company expects to announce additional products shortly.

XYRALID(TM) RC should not be used in patients with a history of sensitivity to any of its ingredients. XYRALID(TM) RC should be used cautiously in those with impaired liver function, as well as the very ill or very elderly and those with significant liver disease. XYRALID(TM) RC should be used with caution in patients receiving antiarrhythmic drugs of Class I. XYRALID(TM) RC is contraindicated for tuberculous or fungal lesions of skin vaccinia, varicella and acute herpes simplex. During and immediately following application of XYRALID(TM) RC, there may be transient stinging or burning from open areas of skin, or transient blanching (lightening), or erythema (redness) of the skin. For external use only. Not for ophthalmic use. Please see package insert for full Prescribing Information.

About Auriga Laboratories(TM)

Auriga Laboratories is a specialty pharmaceutical company building an industry changing commission based-sales model. The company's high-growth business model combines driving revenues through a variable cost commission-based sales structure, acquisition of proven brand names, introduction of new brands, and a strategic development pipeline, all of which is designed to enhance its growing direct relationships with physicians nationwide. Auriga's exclusive prescription and over-the-counter product portfolio includes Aquoral(TM) for the treatment of Xerostomia, Akurza(TM) and Xyralid(TM) dermatology products, and the Zinx(TM), Extendryl®, and Levall® families of products for relief of symptoms associated with a range of acute respiratory diseases. For more information, visit: www.aurigalabs.com.

About Konsyl Pharmaceuticals

Konsyl Pharmaceuticals, Inc. is a subsidiary of ICC Industries, Inc.; a leader in the trading, manufacturing and marketing of chemicals, plastics and pharmaceuticals. Konsyl Pharmaceuticals is a manufacturer and distributor of high quality, natural fiber supplements for improved intestinal and digestive health. The high fiber content of Konsyl products helps consumers to achieve dependable intestinal health. Konsyl fiber products are available in fine pharmacies and chain stores throughout the United States. For more information on Konsyl Pharmaceuticals, Inc. or its complete line of products, contact a company representative at 800-356-6795, or visit the company's website at www.konsyl.com.

1. www.fascrs.org

Forward-Looking Statements

The information contained herein includes forward-looking statements. These statements relate to future events or to the company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause its actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to its operations, results of operations, growth strategy and liquidity. The company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Statements regarding the company's ability to increase its sales force and the success of such sales force in selling its products in light of competitive and other factors, the regulatory status and/or regulatory compliance of its products, the estimated market for hair products, the development of additional products, its ability to sustain market acceptance for its products, its dependence on collaborators, the company's exposure to product liability claims, and the company's prices, future revenues and income and cash flows and other statements that are not historical facts contain predictions, estimates and other forward-looking statements. Although the company believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved and these statements will prove to be accurate. Important factors could cause actual results to differ materially from those included in the forward-looking statements.

http://www.businesswire.com/news/home/20070709005471/en/A.T.S.-Pharmaceuticals-Division-Auriga-Laboratories-Launches-Xyralid